Proteasome inhibition alleviates SNARE-dependent neurodegeneration

Science Translational Medicine

Volumn 4, Issue 147, 2012, Pages

  Sharma, Manu ^a   Burré, Jacqueline ^a   Südhof, Thomas C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE STRING PROTEIN; CYSTEINE STRING PROTEIN ALPHA; EPOXOMICIN; LACTACYSTIN; PROTEASOME; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; AUTOPSY; BRAIN TISSUE; CELL DENSITY; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOTOR COORDINATION; MOUSE; MUSCLE STRENGTH; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SURVIVAL RATE; SYNAPSE; WEIGHT GAIN;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELLS, CULTURED; HSP40 HEAT-SHOCK PROTEINS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; PHENOTYPE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SNARE PROTEINS;

EID: 84865122869     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004028     Document Type: Article

References (44)

1. A. M. Cuervo, E. S. Wong, M. Martinez-Vicente, Protein degradation, aggregation, and misfolding. Mov. Disord. 25 (Suppl. 1), S49-S54 (2010).
2. V. N. Uversky, α-Synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci. 9, 507-540 (2008).
3. L. Kupfer, W. Hinrichs, M. H. Groschup, Prion protein misfolding. Curr. Mol. Med. 9, 826-835 (2009).
4. K. K. Chung, V. L. Dawson, T. M. Dawson, The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24 (Suppl. 11), S7-S14 (2001).
5. A. Ciechanover, P. Brundin, The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 40, 427-446 (2003).
6. C. W. Olanow, K. S. McNaught, Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 21, 1806-1823 (2006).
7. Q. Ding, J. N. Keller, Does proteasome inhibition play a role in mediating neuropathology and neuron death in Alzheimer's disease? J. Alzheimers Dis. 5, 241-245 (2003).
8. B. H. Lee, M. J. Lee, S. Park, D. C. Oh, S. Elsasser, P. C. Chen, C. Gartner, N. Dimova, J. Hanna, S. P. Gygi, S. M. Wilson, R. W. King, D. Finley, Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184 (2010).
9. P. Maher, Proteasome inhibitors prevent oxidative stress-induced nerve cell death by a novel mechanism. Biochem. Pharmacol. 75, 1994-2006 (2008).
10. A. Favit, M. Grimaldi, D. L. Alkon, Prevention of β-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway. J. Neurochem. 75, 1258-1263 (2000).
11. M. Sharma, J. Burré, T. C. Südhof, CSPα promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. Nat. Cell Biol. 13, 30-39 (2011).
12. M. Sharma, J. Burré, P. Bronk, Y. Zhang, W. Xu, T. C. Südhof, CSPα knockout causes neurodegeneration by impairing SNAP-25 function. EMBO J. 31, 829-841 (2011).
13. L. H. Chamberlain, R. D. Burgoyne, The molecular chaperone function of the secretory vesicle cysteine string proteins. J. Biol. Chem. 272, 31420-31426 (1997).
14. S. Tobaben, P. Thakur, R. Fernández-Chacón, T. C. Südhof, J. Rettig, B. Stahl, A trimeric protein complex functions as a synaptic chaperone machine. Neuron 31, 987-999 (2001).
15. L. Nosková, V. Stránecký, H. Hartmannová, A. Přistoupilová, V. Barešová, R. Ivánek, H. Hůlková, H. Jahnová, J. van der Zee, J. F. Staropoli, K. B. Sims, J. Tyynelä, C. Van Broeckhoven, P. C. Nijssen, S. E. Mole, M. Elleder, S. Kmoch, Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am. J. Hum. Genet. 89, 241-252 (2011).
16. B. A. Benitez, D. Alvarado, Y. Cai, K. Mayo, S. Chakraverty, J. Norton, J. C. Morris, M. S. Sands, A. Goate, C. Cruchaga, Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One 6, e26741 (2011).
17. R. Fernández-Chacón, M. Wölfel, H. Nishimune, L. Tabares, F. Schmitz, M. Castellano-Muñoz, C. Rosenmund, M. L. Montesinos, J. R. Sanes, R. Schneggenburger, T. C. Südhof, The synaptic vesicle protein CSPa prevents presynaptic degeneration. Neuron 42, 237-251 (2004).
18. S. Chandra, G. Gallardo, R. Fernández-Chacón, O. M. Schlüter, T. C. Südhof, α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123, 383-396 (2005).
19. K. E. Zinsmaier, K. K. Eberle, E. Buchner, N. Walter, S. Benzer, Paralysis and early death in cysteine string protein mutants of Drosophila. Science 263, 977-980 (1994).
20. P. García-Junco-Clemente, G. Cantero, L. Gómez- Sánchez, P. Linares-Clemente, J. A.Martínez-López, R. Luján, R. Fernández-Chacón, Cysteine string protein-a prevents activity-dependent degeneration in GABAergic synapses. J. Neurosci. 30, 7377-7391 (2010).
21. D. C. Rubinsztein, The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786 (2006).
22. L. Meng, R. Mohan, B. H. Kwok, M. Elofsson, N. Sin, C. M. Crews, Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 96, 10403-10408 (1999).
23. T. Hayashi, H. McMahon, S. Yamasaki, T. Binz, Y. Hata, T. C. Südhof, H. Niemann, Synaptic vesicle membrane fusion complex: Action of clostridial neurotoxins on assembly. EMBO J. 13, 5051-5061 (1994).
24. M. S. Beeri, V. Haroutunian, J. Schmeidler, M. Sano, P. Fam, A. Kavanaugh, A. M. Barr, W. G. Honer, P. Katsel, Synaptic protein deficits are associated with dementia irrespective of extreme old age. Neurobiol. Aging 33, 1125.e1-1125.e8 (2012).
25. E. Head, M. M. Corrada, K. Kahle-Wrobleski, R. C. Kim, F. Sarsoza, M. Goodus, C. H. Kawas, Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol. Aging 30, 1125-1134 (2009).
26. C. L. Ward, S. Omura, R. R. Kopito, Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121-127 (1995).
27. K. Hirano, C. Zuber, J. Roth, M. Ziak, The proteasome is involved in the degradation of different aquaporin-2 mutants causing nephrogenic diabetes insipidus. Am. J. Pathol. 163, 111-120 (2003).
28. S. M. Lee, J. A. Olzmann, L. S. Chin, L. Li, Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways. J. Cell Sci. 124, 3319-3331 (2011).
29. F. Wang, W. Song, G. Brancati, L. Segatori, Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J. Biol. Chem. 286, 43454-43464 (2011).
30. Y. Shimada, H. Nishida, Y. Nishiyama, H. Kobayashi, T. Higuchi, Y. Eto, H. Ida, T. Ohashi, Proteasome inhibitors improve the function of mutant lysosomal α-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation. Biochem. Biophys. Res. Commun. 415, 274-278 (2011).
31. J. T. Young, J. J. Heikkila, Proteasome inhibition induces hsp30 and hsp70 gene expression as well as the acquisition of thermotolerance in Xenopus laevis A6 cells. Cell Stress Chaperones 15, 323-334 (2010).
32. Y. Kawazoe, A. Nakai, M. Tanabe, K. Nagata, Proteasome inhibition leads to the activation of all members of the heat-shock-factor family. Eur. J. Biochem. 255, 356-362 (1998).
33. J. J. Wright, Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy. Clin. Cancer Res. 16, 4094-4104 (2010).
34. J. Sterz, I. von Metzler, J. C. Hahne, B. Lamottke, J. Rademacher, U. Heider, E. Terpos, O. Sezer, The potential of proteasome inhibitors in cancer therapy. Expert Opin. Investig. Drugs 17, 879-895 (2008).
35. J. Sterz, C. Jakob, U. Kuckelkorn, U. Heider, M. Mieth, L. Kleeberg, M. Kaiser, P. M. Kloetzel, O. Sezer, I. von Metzler, BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. Eur. J. Haematol. 85, 99-107 (2010).
36. A. Mullard, Next-generation proteasome blockers promise safer cancer therapy. Nat. Med. 18, 7 (2012).
37. G. Fenteany, R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, S. L. Schreiber, Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731 (1995).
38. L. Meng, R. Mohan, B. H. Kwok, M. Elofsson, N. Sin, C. M. Crews, Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 96, 10403-10408 (1999).
39. R. J. Carter, L. A. Lione, T. Humby, L. Mangiarini, A. Mahal, G. P. Bates, S. B. Dunnett, A. J. Morton, Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 3248-3257 (1999).
40. G. Gallardo, O. M. Schlüter, T. C. Südhof, A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat. Neurosci. 11, 301-308 (2008).
41. S. C. Fowler, B. R. Birkestrand, R. Chen, S. J. Moss, E. Vorontsova, G. Wang, T. J. Zarcone, A force-plate actometer for quantitating rodent behaviors: Illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J. Neurosci. Methods 107, 107-124 (2001).
42. J. Tang, A. Maximov, O. H. Shin, H. Dai, J. Rizo, T. C. Südhof, A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis. Cell 126, 1175-1187 (2006).
43. A. Maximov, Z. P. Pang, D. G. Tervo, T. C. Südhof, Monitoring synaptic transmission in primary neuronal cultures using local extracellular stimulation. J. Neurosci. Methods 161, 75-87 (2007).
44. T. W. Rosahl, D. Spillane, M. Missler, J. Herz, D. K. Selig, J. R. Wolff, R. E. Hammer, R. C. Malenka, T. C. Südhof, Essential functions of synapsins I and II in synaptic vesicle regulation. Nature 375, 488-493 (1995).